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Autophagy-induced RelB/p52 activation mediates
tumour-associated macrophage repolarisation and
suppression of hepatocellular carcinoma by natural
compound baicalin
H-Y Tan1,5, N Wang1,5, K Man2, S-W Tsao3, C-M Che4 and Y Feng*,1
The plasticity of tumour-associated macrophages (TAMs) has implicated an influential role in hepatocellular carcinoma (HCC).
Repolarisation of TAM towards M1 phenotype characterises an immune-competent microenvironment that favours tumour
regression. To investigate the role and mechanism of TAM repolarisation in suppression of HCC by a natural compound baicalin,
Orthotopic HCC implantation model was used to investigate the effect of baicalin on HCC; liposome-clodronate was introduced to
suppress macrophage populations in mice; bone marrow-derived monocytes (BMDMs) were induced to unpolarised, M1-like, M2-
like macrophages and TAM using different conditioned medium. We observed that oral administration of baicalin (50 mg/kg)
completely blocked orthotopic growth of implanted HCC. Suppression of HCC by baicalin was diminished when mice macrophage
was removed by clodronate treatment. Baicalin induced repolarisation of TAM to M1-like phenotype without specific toxicity to
either phenotype of macrophages. Baicalin initiated TAM reprogramming to M1-like macrophage, and promoted pro-inflammatory
cytokines production. Co-culturing of HCC cells with baicalin-treated TAMs resulted in reduced proliferation and motility in HCC.
Baicalin had minimal effect on derivation of macrophage polarisation factors by HCC cells, while directly induced repolarisation of
TAM and M2-like macrophage. This effect was associated with elevated autophagy, and transcriptional activation of RelB/p52
pathway. Suppression of autophagy or RelB abolished skewing of baicalin-treated TAM. Autophagic degradation of TRAF2 in
baicalin-treated TAM might be responsible for RelB/p52 activation. Our findings unveil the essential role of TAM repolarisation in
suppressive effect of baicalin on HCC, which requires autophagy-associated activation of RelB/p52.
Cell Death and Disease (2015) 6, e1942; doi:10.1038/cddis.2015.271; published online 22 October 2015
Liver cancer is the second most fatal cancer worldwide, with
mortality rate of over 84% within 5 years.1 Of 782 000 cases
reported worldwide in 2012, China alone has accounted for
more than 50% of the total incidences. Hepatocellular
carcinoma (HCC) is the major occurring liver cancers, which
represents 70–85% of cases among all primary liver cancers.2
Our recent study postulated that poor prognosis of HCC is
associated with high level of tumour-associated macrophages
(M2) markers and M2 macrophages further enhanced HCC
invasiveness.3 Injection of M2 macrophages could signifi-
cantly promote tumour growth in orthotopic HCC-implanted
mice, which further demonstrated the pro-tumoral role of M2
macrophage in HCC. Reprogramming of TAM away from
M2-like, towards M1-like phenotype in tumour microenviron-
ment by FDA-approved anti-HCC drug sorafenib suppressed
hepatoma cell proliferation.4 These studies suggested the
possibility of targeting TAMs as a potential immune-
modulating strategy in HCC.
Recent studies increased attention on the plasticity of macro-
phage in disease progression and control. Under pathological
and pharmacological conditions, macrophages acquire dis-
tinct phenotypic characteristics through different activation
mechanisms. The classical activated macrophage (M1-like),
exhibits pro-inflammatory properties by expressing and
secreting pro-inflammatory molecules including TNF-α, IL6,
IL12, IL1, Type I IFNγ, CXCL1–3, CXCL-5 and CXCL8–10;
while macrophage could be alternatively activated to M2-like
phenotype, which expresses anti-inflammatory factors such
as IL10.5 M1-like macrophage, which strongly expresses
CD86, iNOS and MHC-II, is distinguishable in phenotype from
M2-like macrophage that has a higher level of CD206, CD163,
YM1 and Fizz1.6 Tumour-associated macrophages (TAMs)
are a population of macrophages in tumour microenvironment,
which functions in promoting cancer cell proliferation and
invasion, regulating tumour neovascularization as well as
cytotoxic T-cell function.7,8 TAMs are predominantly M2
phenotype and exhibits immunosuppressive function. M2
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macrophages tend to secrete pro-tumoral cytokines that
support tumour growth and suppress T-cell proliferation.
Depending on the tumour environment, TAMs phenotype
would be reprogrammed to M1-like that are characterised for
its antigen-presenting property and pro-inflammatory function,
favours tumour regression.9,10
In particular, the role of nuclear factor-kappa B (NF-κB) in
TAMs is enormously studied in recent years. NF-κB transcrip-
tion factor is composed of five protein members including
p100/p52, RelB, p105/p50, RelA and c-Rel.11 Formation and
regulation of transcription activities of NF-κB dimers could be
achieved by both canonical and non-canonical pathways.
Although NF-κB activation is generally considered to trigger
pro-inflammation, it is still not conclusive whether it is
necessarily in regulating the polarisation of TAMs. In fact, the
role of NF-κB in TAMs skewing seems to be controversial
across different studies. It was shown that NF-κB activity was
suppressed in TAMs co-cultured with ovarian cancer stem
cells, which is responsible for theM2macrophages skewing;12
while in ATP-binding cassette transporter G1 (ABCG1)-
knockout TAMs, NF-κB activity was increased and TAMs
exhibited M1 phenotypes and direct toxicity to tumor cells.13
Devaraj and colleagues showed that C-reactive protein could
repolarise M2 macrophages to M1 phenotype, but it fails
to prime those M2 macrophages with inactive NF-κB.14
Combination treatment of TGF-β inhibitor with TLR7 ligand
on TAMs leads to M1 reprogramming and associated with
obvious nuclear translocation of NF-κB;15 TLR9 ligand
combined with IL-10 receptor antibody and CCL16 may
activate NF-κB and redirect TAMs towards M1 phenotype.16
Treatments were also designed in targeting on NF-κB in TAMs.
A small molecule azithromycin inhibits TLR4-related NF-κB
activity, which leads to reduction of M1 and increase of M2
cytokines;17 TAMs challenged with zoledronic acid achieved
M1 phenotypeswith increase of NF-κB-inducible M1 cytokines
expression;18 miRNAs-containing exosomes derived from
Epigallocatechin gallate-treated tumour cells could be
absorbed by TAMs, and led to elicited NF-κB-associated M1
skewing.19 But the role of NF-κB in TAM polarisation is far
more complicated and not just depends on the expression
level of NF-κB components. It was found that p50-knockout
TAMs or TAMs with RNA interference against p50 normally
produce M1 cytokines, and reduced expression of p50 may
switch M2-like macrophages to M1 phenotype.20,21 However,
overexpression of p50 was also suggested to defect NF-κB
pathway and led to M2 phenotype in cancer.22,23 It was also
observed that activation of IKKβ/NF-κB is required for
maintaining M2 phenotype.24 Prostate cancer cell-derived
CCN3 induced NF-κB activation in macrophages and skewed
TAMs to M2 phenotypes;25 an in vivo NF-κB decoy may cause
TAMs polarisation to M2 phenotype.26 All the above studies
revealed the controversy of NF-κB activation in TAMs
polarisation and it is somehow considered to be highly
dependent on different tumour types and experimental
approaches.11 Chan et al.27 even demonstrated that NF-κB
activity is responsible for both M1- and M2-cytokines expres-
sion in human cytomegalovirus-infected macrophages. The
nature of stimulus and physiological content may determine
the role of NF-κB in TAMs polarisation.23
Baicalin is a natural flavonoid present in several medicinal
plants including Scutellaria baicalensis Georgi. Few studies
have revealed the anti-tumour action of baicalin with in vitro
cellular HCC models.28,29 It was also reported that baicalin may
be an immunomodulatory agent by affecting Th17 cells30 and
dendritic cells.31 It was highlighted that immune response may
be boosted up by baicalin treatment via increased expressions
of IFNγ and IL12, which are the essential factors for activating all
types of acquired immune response.32 This prompts us to take
an insight into the action andmechanism of baicalin for potential
cancer therapy. We investigated the impact of baicalin on
repolarisation of TAMand its role inmediating HCC inhibition, as
well as elaborated the mechanism underlying baicalin-induced
autophagy in regulating TAM repolarisation.
Results
Inhibition of orthotopic HCC growth by baicalin requires
presence of macrophages. Few previous studies reported
that baicalin may exhibit anti-tumour effect on HCC cells
in vitro,33,34 but investigation on the action of baicalin in vivo
and its underlying mechanism remains scanty. To system-
atically evaluate the anti-tumour action of baicalin on HCC,
we introduced an orthotopic HCC-implanted murine model by
embedding small cubes of subcutaneously grown tumour
onto the right lobe of mice liver, which has been reported in
our previous studies,33–36 followed by oral administration of
baicalin (50mg/kg) every alternate day after 1 week of
transplantation. Body weight of mice was monitored once per
week and there was no weight loss among the groups
after 5 weeks of intervention (Supplementary Figure S1).
Five-week treatment of baicalin could completely inhibit
orthotopic HCC growth in mice, while relapse of tumour
was observed in mice with macrophage removal (Figure 1b).
The tumour size in macrophage-depleted mice with baicalin
was not as large as that in macrophage-presenting mice
without baicalin treatment; and significant relapse of tumour
in macrophage-depleted mice in comparison to macrophage-
presenting mice treated with baicalin revealed that macro-
phage is involved in mediating the anti-tumour effect of
baicalin (Figure 1c). Immunohistochemistry staining with
F4/80 antibody showed successful removal of macrophage
by liposomal clodronate treatment, and baicalin did not
significantly increase the residence of macrophage in liver.
All these indicated that the role of macrophage in mediating
anti-tumour effect of baicalin is independent to the increase
of macrophages infiltration (Figure 1d). This was further
evidenced by the observation that there was no significant
increase in inflammatory monocyte in bone marrow or
circulating system of baicalin-treated mice (Figures 1e and f).
Our results reveal that macrophage has a positive role in
regulating the anti-tumour effect of baicalin in HCC.
Baicalin skews macrophages away from M2-like, towards
M1-like phenotype. A plenty of studies have revealed
that carcinogenesis involves a process of macrophage
infiltration into tumour microenvironment followed by
polarisation of macrophage by tumour-favouring factors.37
Infiltrated macrophages are programmed to anti-inflammatory
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M2-like phenotype, which protects tumour cells from
immune surveillance.38 M1-like macrophages produce
pro-inflammatory cytokines (TNF-α, IL12, iNOS, etc), which
are against tumour cell growth, whereas M2-like phenotype
secrets a series of tumour-favouring factors (IL10, TGF-β,
Arginase1, etc) that promote tumour expansion.39 To
examine if baicalin could re-programme intrahepatic macro-
phages towards M1-like phenotype, we measured the
presence of M1/M2-like macrophages in the liver of
baicalin-treated mice. Baicalin treatment increased the iNOS+
M1-like macrophages population while significant reduction
of MR+ M2-like population in liver tissue of mice (Figure 2a).
We also found that baicalin exhibited no specific cytotoxicity
to M1/M2-like macrophages (Figure 2a), which indicated that
the effect of baicalin on intrahepatic macrophages phenotype
differentiation is independent to cell viability. To further
classify the phenotype of baicalin-treated macrophages, we
introduced two cell surface markers to distinguish M1-like
phenotype from M2. M1-like macrophage possessed rela-
tively higher expression of CD86 while M2-like macrophage
highly expressed CD206 (Figure 2c). It was shown that after
7 days of differentiation with HCC tumour supernatant (TSN),
the TSN-derived TAMs exhibited high expression of CD206
with relatively low CD86; indicating TAMs are prone to M2-like
phenotype (Figure 2d). The 48-h treatment of baicalin
re-skewed the TAMs away from M2-like, towards M1-like
phenotype dose-dependently (Figure 2d). Consistent with the
phenotypic analysis, we observed upregulation of the
pro-inflammatory genes, TNF-α and IL12, while downregula-
tion of IL10 and Arginase 1, the anti-inflammatory genes in
baicalin-treated F4/80+ TAMs (Figure 2e). Baicalin-treated
macrophage cells also secreted higher level of pro-
inflammatory cytokines (IL6 and TNF-α) while lower level of
IL10 (Figure 2f), which revealed TAM reprogramming by
Figure 1 Inhibition of orthotopic HCC growth by baicalin requires presence of macrophages. (a) Schematic presentation of experimental design. (b) Removal of macrophage
from mice completely blocked the anti-tumour effect of baicalin. Orthotopic HCC tumour growth in mice (n= 4) with baicalin treatment was not obvious, whereas removal of
macrophage by intraperitoneally injecting clodronate liposome resulted in relapse of hepatic tumour. (c) The size calculation of hepatic tumour. **Po0.01, compared with
liposome control group without baicalin treatment; ΔΔPo0.01, compared with liposome control group with baicalin treatment. (d) The amount of intrahepatic tumour was slightly
increased upon baicalin treatment without significance, while presence of clodronate liposome remarkably reduced hepatic macrophage. (e) Baicalin treatment did not potently
induce production of inflammatory monocytes in bone marrow. (f) Baicalin treatment did not elevate inflammatory monocytes populations in circulating system
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baicalin is functional in regulating cytokine production.
Overall, baicalin promoted the TAM repolarisation towards
M1-like phenotype.
Baicalin induces repolarisation of M2-like macrophage
without affecting M1 phenotype. To further examine the
action of baicalin on repolarisation of differentiated macro-
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phages, we polarised BMDMs-derived macrophages to either
M1-like or M2-like phenotype. The polarised macrophages
were then subject to 48 h treatment of baicalin. Interestingly,
baicalin particularly skewed M2-like macrophages towards
M1-like phenotype, without causing any significant pheno-
typic changes in M1-like macrophage (Figure 3a). This was
further evidenced by the fact that expression of pro-
inflammatory genes in baicalin-treated M2-like macrophages
was increased while anti-inflammatory factors were reduced
(Figure 3b). In M1-like macrophages, expression of pro-
inflammatory genes also increased though no pheno-
typic changes were observed after baicalin
treatment, indicating that baicalin treatment could promote
pro-inflammatory cytokines production. Consistent observa-
tion was obtained in culture supernatant of both M1-like and
M2-like macrophages with baicalin treatment (Figure 3c). As
M1-like TAMs may exert their anti-tumour action by producing
pro-inflammatory cytokines,40 these observations revealed
that baicalin treatment may result in polarised macrophages
in tumour microenvironment prone to acquire anti-tumour
functions. And the effect of baicalin on TAMs repolarisation in
tumour microenvironment may be independent to any
changes in polarisation factors derived by tumour cells itself,
as phenotypic analysis showed that TAMs cultured with TSN
from HCC cells with pre-treatment of baicalin were not prone
to M1-like phenotype (Figure 3d). All the above observations
confirmed the direct reprogramming action of baicalin on
polarised TAMs. Furthermore, co-culturing of baicalin-pre-
treated TAMs with HCC cells suppressed motility of cancer
cells. HCC cells were seeded with 100% confluence in
24-well cell culture plate and a gap was created by scraping
with a 10-μl pipette tip at the centre of the monolayer.
Then HCC cells were subject to 48 h co-culturing with TAMs
pre-treated with vehicle or 20 μM baicalin for 48 h. HCC cells
co-cultured with baicalin-pre-treated TAMs exhibited slow
migration towards centre of the gap (Figure 3e, Po0.01).
Also, co-culturing of baicalin-pre-treated TAMs inhibited
proliferation of HCC cells. HCC cells (1 × 104) were seeded
and were subject to a co-culturing with TAMs pre-treated with
vehicle or 20 μM baicalin. Number of HCC cells was counted
at day 3, 6 and 9. Reduced proliferation of HCC cells was
observed in time-dependent manner (Figure 3f, Po0.01).
Our results indicate that baicalin suppressed tumour cell
expansion by incurring direct reprogramming effect on
polarised macrophages.
Induction of autophagy is involved in repolarisation of
baicalin-treated TAMs. Some previous studies have
reported the property of baicalin as a natural autophagy
inducer in cancer cells,34,41 and consistently, we observed
increased of LC3-II/LC3-I ratio in baicalin-treated TAMs. The
conversion of cytoplasmic form of LC3 into membrane form in
baicalin-treated TAMs indicated induction of autophagy
(Figure 4a). We also observed autophagy induction in TAMs
on liver tissue of HCC bearing mice (Supplementary Figure 7).
Elevated LC3 punctuation in baicalin-treated TAMs further
proved the autophagy initiation, and baicalin-induced auto-
phagy could be blocked by RNA interference against
autophagy essential gene Atg5 (Figure 4b). It was found that
induction of autophagy by baicalin could only be achieved in
unpolarised and M2-like macrophages but not in M1-like
macrophages (Figure 4c). Considering that,42 this finding
may indicate autophagy plays a role in baicalin-induced
macrophage polarisation. To prove this hypothesis, we used
Bafilomycin A1 and RNA interference against Atg5 gene to
suppress induction of autophagy in TAMs. Pharmacological
inhibition of autophagy by Bafilomycin A1 abolished repolar-
isation of TAM by baicalin towards M1-like phenotype
(Figure 4d), and it was further confirmed by reduced
pro-inflammatory genes and elevated anti-inflammatory
genes in baicalin-treated TAMs in the presence of Bafilomy-
cin A1 (Figure 4e). Consistent observations was obtained on
reprogramming of baicalin-treated TAMs towards M2-like
phenotype upon Atg5 depletion, and reverted changes of
relative gene expression induced by baicalin (Figures 4f and
g). These observations confirmed autophagy is involved in
reprogramming of TAM induced by baicalin.
Autophagy-associated activation of RelB/p52 pathway
mediates repolarisation of TAM by baicalin. To explore the
mechanism underlying autophagy-induced repolarisation of
TAM by baicalin, we examined the activation of RelB/p52
pathway, which was reported to dominate reprogramming of
Th1 cells to Th2 phenotype.43 Increased RelB expression
was observed in baicalin-treated TAMs, which could be
attenuated by depletion of Atg5 (Figure 5a). Interestingly, it
was observed that in baicalin-treated TAMs, the mRNA
expression of RelB was elevated (Supplementary Figure S2).
The consistent increase of phosphorylation of p100 and p52
in baicalin-treated TAMs revealed that the transcriptional
increase of RelB may be due to the positive feedback loop of
Figure 2 Treatment of baicalin results in reprogramming of M2-like TAMs to M1-like phenotype. (a) Baicalin treatment resulted in increase of hepatic M1-like TAMs with
reduced M2-like populations. Antibodies against iNOS (M1-like marker) and mannose receptor (MR, M2-like marker) were used to stain frozen-sectioned liver tissue. Increase of
iNOS-positive cells all over the liver of baicalin-treated mice was observed (Po0.01); while hepatic MR-positive cells within non-tumour and peri-tumour area was remarkably
reduced upon baicalin treatment (Po0.01) (scale bar, 100 μm); (b) baicalin did not cause cell death in any specific type of macrophages. BMDM was cultured and differentiated
as described in Materials and Methods. A relatively high dose of baicalin (80 μM) was given to either M1-like or M2-like TAM for 48 h. Cell viability was determined with flow
cytometry using Annexin V/7-AAD staining. (c) Differentiated BMDM exhibited differential patterns in CD86/CD206 expression. Antibodies against CD86 and CD206 were used to
stain cell surface marker of differentiated BMDMs. F4/80 was co-stained to identify differentiated macrophage population. M1-like macrophage had higher expression of CD86
with lower expression of CD206 (Po0.01), while CD206 was induced and CD86 was relatively low in M2-like macrophage (Po0.01). (d) Baicalin treatment resulted in skewing of
TAM to M1-like macrophage. TAMs were induced by culturing BMDM with tumour supernatant (TSN) as described in Materials and Methods. Cells were subjected to different
doses of baicalin for 48 h. It was observed that baicalin induced skewing of TAMs into M1-like phenotype and away from M2-like in dose-dependent manner. (e) Cytokine profile in
baicalin-treated TAMs favouring M1-like phenotype. RNA from baicalin-treated cells was collected and expression of TNF-α, IL12 (M1-like macrophage markers) and IL10,
Arginase1 (Arg1, M2-like macrophage markers) was determined by quantitative real-time PCR. Increase of M1 markers but decrease of M2 markers was observed in baicalin-
treated TAM (Po0.01). (f) Baicalin treatment induced elevated secretion of pro-inflammatory cytokine in TAMs. Cytokine concentration in cultured TAM supernatant was
determined with CBA kit. TNF-α and IL6 (pro-inflammatory cytokines) levels were increased (Po0.01), while IL10 (anti-inflammatory cytokine) was reduced after baicalin
intervention (Po0.01). Cytokine level was expressed as pg/ml± S.D.
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Figure 3 Baicalin induces repolarisation of M2-like macrophage without affecting M1 phenotype. (a) The 20 μM baicalin treatment repolarised differentiated M2-like
macrophage to M1 phenotype, while minimally affected differentiated M1-like macrophage. BMDMs were cultured and differentiated, then treated with baicalin for 48 h.
Expression of CD86/CD206 was determined (Po0.01). Increase of CD86 expression with CD206 suppression was found in baicalin-treated M2-like macrophage, while baicalin
had minimal effect on the expression of cell surface markers in M1-like macrophage (P40.05). This observation was further evidenced by cytokine expression profile (b) and
cytokine secretion (c). (d) Baicalin had minimal effect on macrophage-polarisation factors derived by tumour cells. TSN was collected from HCC cells treated with either vehicle or
20 μM baicalin, and was used to differentiate BMDMs as described in Materials and Methods. No significant skewing of TAM could be observed. Differentiated M1 macrophages
were used as a positive control. (e) Co-culturing of baicalin-pre-treated TAMs suppressed motility of HCC cells. HCC cells were seeded in 24-well cell culture plate and a gap was
created by scraping with a 10-μl pipette tip at the centre of the monolayer. Then HCC cells were subject to a 48-h co-culturing with TAM pre-treated with vehicle or 20 μM baicalin
for 48 h. HCC cells co-cultured with baicalin-pre-treated TAM exhibited slow migration towards centre of the gap (Po0.01). (f) Co-culturing of baicalin-pre-treated TAM inhibited
proliferation of HCC cells. HCC cells (1 × 104) were seeded and subjected to co-culturing with TAMs pre-treated with vehicle or 20 μM baicalin. Number of HCC cells was counted
at day 3, 6 and 9. Reduced proliferation of HCC cells with baicalin-pre-treated TAM was observed in time manner (Po0.01)
Autophagy triggered RelB/p52 activation
H-Y Tan et al
6
Cell Death and Disease
RelB/p52 activation.44 Co-immunoprecipitation assay with
RelB antibody confirmed association of p52 with RelB in
TAMs, while IκBα was dissociated from the RelB/p52 complex
with baicalin treatment (Figure 5b). Furthermore, it was
observed that RelB and p52 were translocated into nuclear
area of TAMs in the presence of baicalin (Figure 5c), and
transactivated the RelB/p52-specific target genes CCL9 and
CXCL12 (Figure 5d). Inhibition of RelB expression by RNA
interference in baicalin-treated TAMs abolished repolarisation
of TAMs towards M1-like phenotype, and drove the tendency
of TAMs towards M2-like phenotype. Increased expression of
pro-inflammatory cytokines by baicalin was abolished by
RelB suppression, and reduction of anti-inflammatory cyto-
kines was restored (Figure 5f). The high expression of RelB
and p52 in M1-like macrophages instead of in unpolarised
and M2-like macrophages (Figure5g) further confirmed the
role of upregulated RelB in mediating repolarisation of TAM
induced by baicalin.
Activation of RelB/p52 pathway may be dependent on
reduced expression of TRAF2 in baicalin-treated TAMs.
To further prove the mechanism, we observed the expression
of IKKα, the upstream event of RelB/p52. A consistent
upregulation of IKKα was observed in baicalin-treated TAMs,
which was blocked by inhibition of Atg5 (Figure 6a). Similar to
RelB, it was found that expression of IKKα mRNA was
elevated (Supplementary Figure S3), majorly due to the
positive feedback regulation of RelB/p52 activation.45 The
role of IKKα in mediating baicalin-induced RelB activation
was further proved by the observation that IKKα inhibition by
RNA interference attenuated upregulation of RelB expression
(Figure 6b). Interestingly, it was shown that blockade of IKKα
has minimal effect on baicalin-induced autophagy in TAM,
indicating that IKKα positions at the downstream of auto-
phagy (Figure 6c). Silencing of IKKα in baicalin-treated TAMs
restored M2-like phenotypic characteristics of the cells
(Figure 6d), and suppressed pro-inflammatory gene expres-
sion in baicalin-treated TAMs, as well as restored the
expression of anti-inflammatory genes (Figure 6e). As IKKα
also plays a key role in mediating activation of RelA by
inducing phosphorylated-degradation of IκBα,46 which then
activate transcription of pro-inflammatory genes, we exam-
ined if RelA pathway was affected by baicalin treatment in
TAMs. Interestingly, we observed very low expression level of
RelA in TAMs, and baicalin treatment could suppress RelA
even in the presence of soluble TNF-α, a RelA-activating
cytokine (Figure 6f). This was consistent with the previous
report that TLR2 could selectively suppress RelA expression
upon induction of autophagy.47 This data revealed that
repolarisation of TAM by macrophage may be dependent
on activation of RelB but not RelA pathway. In this case, we
then examined the expression of TRAF2/TRAF3 complex,
the negative regulator of RelB pathway, and observed the
reduced expressions of both TRAF2 and TRAF3 (Figure 6g).
Our data may suggest restriction of TRAF2/TRAF3 expres-
sion, the intracellular suppressor of IKKα/RelB/p52 signalling,
may confer repolarisation of TAM by baicalin.
Baicalin initiates autophagic degradation of TRAF2 in
TAMs. In our study, we did not observe reduced mRNA
expression of TRAF2 in baicalin-treated TAM (Supplementary
Figure S4), though protein level of TRAF2 was potently
suppressed (Figure 6g). This inhibitory effect of baicalin on
TRAF2 was completely abolished in the presence of
pharmacological inhibitor of autophagy Bafilomycin A1, or
by depleting Atg5 from TAMs (Figure 6h), indicating that
reduced expression of TRAF2 in baicalin-treated TAMs may
be independent to transcriptional suppression of TRAF2 itself
but dependent on autophagic degradation pathway. And this
effect of baicalin was specific to M2-like macrophages,
as expression of TRAF2 was relatively low in M1-like
macrophages and baicalin showed minimal effect on it
(Figure 6i). This selective autophagic degradation of TRAF2
in baicalin-treated TAMs was further proved by observation of
co-localization of TRAF2 with lysosome and monodansylca-
daverine (MDC), indicating a lysosomal degeneration of
TRAF2 induced by baicalin (Figure 6j and Supplementary
Figure S6). Co-immunoprecipitation assay with LC3 and
TRAF2 antibody also confirmed the association of TRAF2
with LC3 and Atg5 in TAMs after baicalin intervention
(Supplementary Figure S6). Furthermore, a cargo protein of
selectively autophagic degradation, p62, was observed to
attach TRAF2 upon baicalin treatment (Figure 6k). These
observations reveal a lysosomal degradation of TRAF2 is
dependent on baicalin-induced autophagy in TAMs.
Discussions
Macrophages are high-plasticity immune cells, and they
maintain in M1/M2 mixture states under normal condition.
Macrophage M1/M2 state switching may be crucial in
determining the tissue fate.48 High expression of M-CSF and
macrophages markers in peritumoral area of hepatocellular
carcinoma tissue promotes tumour recurrence and meta-
stasis; distribution of M2 macrophages in peritumoral section
is associated with poor prognosis of HCC patients.3,49
Depletion of TAMs further improves the anti-tumour effect
of sorafenib, the current first-line treatment of HCC.50
Therapeutics against M2 macrophage is no doubt, in most of
the studies, benefits cancer therapy. However, the role of M1-
like macrophage is much more complicated as previous
studies showed that the inflammatory environment condi-
tioned by macrophages promoted tumorigenesis and cancer
progression. It was shown that IL6-producing TAM may
promote the expansion of cancer stem cell in HCC.51 Although
phenotype of TAM cannot be identified here, as both M1-like
andM2-likemacrophages could produce IL6,52 it indicates the
role of pro-inflammatory M1 macrophages may not be as
direct as M2 macrophages. A recent study observed that
though TAMwas repolarised towards M1 phenotype and away
from M2 phenotype by sorafenib, the circulating inflammation
condition was reduced by the treatment.4 This may indicate
that skewing of M2-like TAM to M1 phenotype will not promote
systematic inflammation in cancer patients. In fact, HCC
carcinogenesis would request infiltration of inflammatory
leukocytes into the liver, whichmay cause hepatocyte apoptosis
and sustained inflammation.53 Our study, showing that baicalin
did not elevate circulating inflammatory monocytes, revealed
that the compound may be able to repolarise loco-regional TAM
away fromM2phenotypes. In fact, in our co-culture study, we did
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not observe significant apoptosis of HCC cells in the presence of
baicalin-pre-treated TAMs (data not shown), which may indicate
that production of pro-apoptotic factors by baicalin-treated
TAMs, such as TNF-α, is not sufficient to cause death of
HCC cells. Our findings, though baicalin-treated TAMs are
prone to beM1-like, we cannot preclude that reducedHCC cell
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proliferation and migration is not due to the decrease of
M2-like TAM-derived protumoral cytokines.
Furthermore, our study demonstrated that baicalin-mediated
M1 reprogramming is regulated by the downregulation of
TRAF2 via autophagy-dependent pathway. Detailed regula-
tory mechanism is illustrated in Figure 7. TRAF2 is a signalling
protein in response to TNF receptor binding activity, and its
regulation largely affected the downstream NF-кB activation.
In TNF–RII complex, association of TRAF2 with c-IAP1
promotes TRAF2 ubiquitination-dependent degradation.54
The c-IAP1-mediated TRAF2 degradation is required for
monocyte differentiation to functional macrophages.55 It is
Figure 4 Autophagy is involved in baicalin-induced TAM repolarisation. (a) Baicalin treatment induced conversion of LC3-I into LC-II in TAM. BMDM cells were subjected to
RNA interference as described in Materials and Methods with mock scramble negative control or siRNA against murine Atg5. Cells were treated with baicalin for 48 h and protein
was collected for analysis. Increase of LC3-II expression with reduced LC3-I upon baicalin treatment was observed, while suppression of Atg5 attenuated the conversion of LC3-I
into LC-II. (b) Baicalin increased LC3 puncta in TAM. Cells with mock or Atg5 RNA interference were subjected to baicalin treatment. Then cells were stained with LC3B antibody
and visualised under confocal microscope. Increase of LC3 puncta (light green dots) was observed in baicalin-treated TAM, which could be blocked by RNA interference against
Atg5 (magnification: x60). (c) Baicalin could induce autophagy in M2-like macrophage but not in M1-like. Protein expression was detected with immunoblotting. Conversion of
LC3-I into LC3-II was observed in both unpolarised macrophage and M2-like macrophage, but not in M1-like macrophage. (d) Blockade of autophagy by presence of Bafilomycin
A1 resulted in re-skewing of baicalin-treated TAMs into M2 phenotype. Bafilomycin A1 was added to TAM 30 min before the 48-h baicalin treatment. It was observed that presence
of Bafilomycin A1 potently blocked change of CD86 and CD206 expression induced by baicalin. This was further evidenced by observations in cytokine expression profile (e) of
baicalin-treated TAMs with or without Bafilomycin A1. (f) Suppression of autophagy by RNA interference against Atg5 induced re-skewing of baicalin-treated TAM to M2
phenotype. RNA interference was conducted as described and TAMswas subject to baicalin treatment. Suppression of Atg5 expression significantly blocked change of CD86 and
CD206 expressions induced by baicalin. This was further evidenced by observations in cytokine expression profile (g) of baicalin-treated TAM with or without RNA interference
against Atg5
Figure 5 Autophagy-associated activation of RelB/p52 pathway mediates TAM repolarisation induced by baicalin. (a) The induced expression of RelB in baicalin-treated TAM
is associated with autophagy induction. RNA interference against Atg5 was conducted as described and TAMwas treated with 20 μM baicalin for 48 h. Expression of RelB, p-p100
and p52 was detected by immunoblotting. It was shown that baicalin treatment resulted in increase of RelB and p52 expression, as well as phosphorylation of p100, and this effect
of baicalin could be blocked by inhibition of autophagy by RNA interference against Atg5. (b) Baicalin treatment induced association of p52 with RelB. TAM was treated and co-
immunoprecipitation assay was conducted as described. Increased association of RelB with p52 was observed in baicalin-treated TAM. Reduced IκBα with RelB was also
observed. Expression of protein level was normalised by GAPDH as INPUT samples and by RelB as IPed-samples. (c) Baicalin treatment induced nuclear localisation of RelB
and p52. DAPI was used to stain nuclei of the cells. TAM with or without baicalin treatment was fixed and stained with antibodies against RelB and p52, followed by observation
under confocal microscope. Increased RelB and p52 presentation in nuclear area was found in baicalin-treated cells. (d) Elevation of RelB/p52-specific target gene expression
CCL19 and CXCL12 was observed in TAM in the presence of baicalin (magnification: x60). (e) Suppression of RelB by RNA interference induced re-skewing of baicalin-treated
TAMs to M2 phenotype. RNA interference was conducted as described and TAM was subjected to baicalin treatment. Suppression of RelB expression significantly blocked
change of CD86 and CD206 expression induced by baicalin. This was further evidenced by observation in cytokine expression profile (f) of baicalin-treated TAMs with or without
RNA interference against RelB. (g) Expression of RelB and p52 in different phenotypes of macrophages. BMDMs were cultured and differentiated as described and protein was
collected for analysis. It was observed that RelB and p52 were highly expressed in M1-like macrophage but not in either unpolarised or M2-like macrophage
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surprising that we found the blockade of autophagy also
inhibited TRAF2 reduction, suggesting TRAF2 may be
degraded in lysosome apart from the conventional
proteasomal-related pathway. Although this scenario may be
rare; the notion is supported by a recent study on TRAF2
lysosomal-dependent degradation mediated by zinc finger
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protein A20.56 We indeed observed the ubiquitination of
TRAF2 (Supplementary Figure S5) and colocalization of
TRAF2 with lysosomal tracker p62, the autophagy-related
protein that cargo ubiquitinated intracellular molecules, which
was recruited to autophagosome during autophagy process
and lead to the targeted molecules degraded through
lysosomal pathway.57 The interaction between ubiquitinated
TRAF2 and p62may explain TRAF2-lysosomal degradation is
autophagy dependent. All these collectively suggest the
recruitment of ubiquitinated TRAF2 to lysosomal compart-
ments for clearance.
In our study, baicalin-mediated downregulation of TRAF2
promotes sustained activation of IKKα and RelB. IKKα is a
tumour promoter in the context of colorectal cancer that is
responsible in blocking the recruitment of M1-like myeloid
cells.58 IKKα and RelB are important regulators of non-
canonical NF-кB signalling and p100 processing contributes
to the activation of RelB/p52 complex, while TRAF2 negatively
regulates the pathway.59 Inactive form of RelB is associated
with IкBα and it mobilises to nucleus followed by IкBα
degradation.60 RelB is associated with p52 to activate
transcription of target genes. This non-canonical activation
of NF-кB pathway has been reported to dominate the
reprogramming of Th1 cells into Th2 phenotype in cells other
than macrophage.43 Besides, study has showed high nuclear
p50 concentration in TAMs associated with M2-like
phenotype, while TAMs isolated from p50-knockout mice
expressed M1-like cytokines.21 The inhibitory effect of
p50 on M1-reprogramming may be due to the suppression
of NF-κB transcriptional activities through formation of p50
homodimers.61 As p50 lacks of transactivation domain,
p50/p50 homodimer is supposed to compete with p65/p50
heterodimer, which is able to activate transcription of pro-
inflammatory genes.11 In fact, p52, the non-canonical NF-κB
pathway member, which also lacks of transactivation domain,
is able to bind to itself or with p50 to act as a repressor of NF-κB
activation.62 These evidences showed that activation of NF-κB
pathway does not merely depend on increased expression of
p50 or p52. It was addressed that the binding of NF-κB dimers
is highly adaptive to cellular situation. As the transactivation of
pro-inflammatory genes by NF-κB dimers is transient and
under dynamic equilibrium, the nature of dimers are depen-
dent on the given cellular concentrations of NF-κB
components.63 In our study, we found that RelB is increased
upon baicalin treatment. Increase of RelBmay in turn results in
conversion of repressive p52 dimers to RelB/p52 heterodi-
mers, which are able to transactive M1 genes expression.
This was evidenced by previous study that challenging
macrophages with LPS induced RelB expression, which
in consequence increased transcription of non-canonical
NF-κB-targeted gene ELC.62 Also, this was consistent with
previous observation that production of RelB is a major
contributing factor in activation of non-canonical NF-κB
pathways.64 Study also revealed that removal of RelA by
autophagy, the core molecule of canonical NF-кB pathway,
may lead to M2 polarisation of macrophage,47 though there is
still no direct evidence to show any essential role of RelA
pathway activation in mediating macrophage reprogramming.
This is consistent with our observation that baicalin-induced
autophagy also resulted in RelA degradation in TAM.
However, as baicalin-induced autophagy particularly pro-
motes TRAF2 degradation-associated activation of RelB/p52
pathway; the effect of RelA degradation on TAM polarity
seems to be compensated. In addition, it was found that
production of pro-inflammatory stimuli particularly results in
RelB activation but independent to RelA pathway in
Figure 7 The mechanism underlying repolarisation of baicalin-treated TAMs to
M1 phenotype
Figure 6 Autophagy-induced TRAF2 degradation may be associated with the activation of RelB/p52 pathway in baicalin-treated TAMs. (a) Induced expression of IKKα in
baicalin-treated TAMs is associated with autophagy induction. RNA interference against Atg5 was conducted as described and TAM was treated with 20 μM baicalin for 48 h.
Expression of IKKα was detected by immunoblotting. It was shown that baicalin treatment resulted in increase of IKKα expression, which could be blocked by inhibition of
autophagy by RNA interference against Atg5. (b) Silencing of IKKα expression attenuated RelB overexpression in baicalin-treated TAM. RNA interference against IKKα was
conducted as described and TAM was treated with 20 μM baicalin for 48 h. It was shown that increased expression of RelB by baicalin was attenuated upon IKKα suppression.
(c) Autophagy induction is independent to IKKα overexpression. (d) Suppression of IKKα by RNA interference induced re-skewing of baicalin-treated TAM to M2 phenotype. RNA
interference was conducted as described and TAM was subjected to baicalin treatment. Suppression of IKKα expression significantly blocked change of CD86 and CD206
expression induced by baicalin. This was further evidenced by observation in cytokine expression profile (e) of baicalin-treated TAMs with or without RNA interference against
IKKα. (f) RelA pathway may not be activated upon baicalin treatment. TAM was treated with baicalin in the presence of soluble TNF-α. Expression of RelA and IκBα was
determined. (g) Baicalin treatment induced reduction of TRAF2 and TRAF3 expression. (h) Baicalin-suppressed TRAF2 expression may be blocked when autophagy was
blocked by either Bafilomycin A1 or RNA interference against Atg5. (i) Baicalin induced TRAF2 degradation in M2-like macrophage but not in M1 phenotype. (j) Degradation of
TRAF2 induced by baicalin may be dependent on autophagy-associated lysosomal pathway. TAM treated with or without baicalin was fixed and stained with TRAF2 antibody.
Lysosome was stained with Lysotracker Green for 30 min. It was observed that TRAF2 was translocated to lysosome after treatment of baicalin in TAM (magnification: x60).
(k) p62 cargo protein may dominate selective autophagic degradation of TRAF2 in baicalin-treated TAM. TAM was treated with or without baicalin in the presence of lysosome
inhibitor leupeptin. Co-immunoprecipitation assay was conducted with TRAF2 antibody and association of p62 with TRAF2 was detected by immunoblotting. Recruitment of p62
to TRAF2 upon baicalin treatment was observed
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macrophage,62 which is consistent with our observation that
RelB and p52 highly expressed in M1-like but not M2-like
macrophage. A positive feedback loop in RelB pathway in
baicalin-treated TAM resembles classical activation of macro-
phages into M1-like phenotype.
In conclusion, our data postulate that the tumour suppres-
sive effect of baicalin was mediated by re-education of TAMs
away from M2-like, towards tumour inhibiting M1-like pheno-
type. This effect was regulated by activation of RelB/p52
pathway via TRAF2 lysosomal degradation-dependent pathway.
Baicalin-induced autophagy was responsible for lysosomal
degradation of TRAF2 as well as TAM repolarisation. This
study proposes baicalin as a potential immune therapeutic
candidate for the treatment of hepatocellular carcinoma.
Materials and Methods
Chemical, reagents and antibodies. Baicalin, Bafilomycin A1 and
leupeptin were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibody
against MR was obtained from Abcam (Cambridge, UK); antibody against CD11b,
Ly6C, CD115, F4/80, CD86 and CD206 were from eBioscience (CA, USA);
antibodies against LC3B and iNOS was purchased from Novus Biologicals
(Littleton, CO, USA); Antibodies against phosphor-p100, RelA, IKKα, RelB, TRAF2,
TRAF3 IкBα, GADPH, were purchased from Cell Signalling Technology (MA, USA);
The FITC-conjugated secondary antibody and LysoTracker Green were from
Molecular Probe (Eugene, OR, USA), murine recombinant proteins M-CSF, IFNɣ
and IL4 were from Peprotech (NJ, USA).
Cells, orthotopic HCC implantation animal model and macro-
phage removal. In vitro and in vivo models of interaction between HCC cells
have been established and used in our previous studies.36 HCC cell line MHCC97L
cells were provided by Professor Man Kwan in Department of Surgery, University of
Hong Kong, and were maintained in DMEM supplemented with 10% fetal bovine
serum. Murine orthotopic HCC model was established on BALB/cAnN-nu athymic
mice. Removal of macrophage from mice was conducted as indicated in Figure 1a.
In brief, 2 days before the implantation of HCC generated by MHCC97L cells, mice
in macrophage-removal group (MΦ− ) was given clodronate liposome via
intraperitoneal injection once (0.1 ml/10 g, ClodronateLiposomes.com, the Nether-
lands) to deplete macrophage from mice. Macrophage removal was then conducted
throughout the experiment by liposomal clodronate treatment every 4 days. Mice in
macrophage-presenting groups (MΦ+) received equal volume of PBS liposome as
control. A small cube (~1 mm3) of HCC tumour was implanted into the left lobe of
mice liver. Presence of liver tumour was checked 1 week after implantation by
laparotomy. Mice in macrophage-presenting groups were then given baicalin
(50 mg/kg per 2 days) or equal volume of PBS (n= 4). All mice were sacrificed after
5 weeks of treatment. The study protocols were approved by the Committee on the
Use of Live Animals in Teaching and Research (CULATR) of The University of Hong
Kong, Hong Kong (reference number: 2809-12). Size of the tumour (mm3) was
measured as (length × width)2/2. The myeloid cells from bone marrow and
circulating system were isolated for further flow cytometry analysis.
Statistical analysis. Studies were performed in triplicate except particular
notice in figures. Data were expressed as mean± S.D. Statistical significance were
analysed using one-way ANOVA followed by Newman–Keuls post hoc test, and
P-valueo0.05 considered as significant.
Other Materials and Methods were present in Supplementary Methods.
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